NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free FBRX Stock Alerts $0.59 -0.03 (-4.81%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.57▼$0.6150-Day Range$0.58▼$0.7852-Week Range$0.38▼$1.06Volume9,172 shsAverage Volume26,279 shsMarket Capitalization$21.64 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Forte Biosciences alerts: Email Address Forte Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside468.4% Upside$3.38 Price TargetShort InterestHealthy0.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.25 out of 5 starsMedical Sector331st out of 924 stocksPharmaceutical Preparations Industry148th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingForte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the outstanding shares of Forte Biosciences have been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 12.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBRX. Previous Next 2.1 News and Social Media Coverage News SentimentForte Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Forte Biosciences this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($0.59) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesJune 1 at 1:26 AM | americanbankingnews.comEquities Analysts Set Expectations for Forte Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:FBRX)May 30 at 8:22 AM | americanbankingnews.comForte Biosciences (NASDAQ:FBRX) Coverage Initiated at Brookline Capital ManagementMay 30 at 2:30 AM | americanbankingnews.comForte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)May 21, 2024 | finance.yahoo.comCompanies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite RiskyMay 17, 2024 | businesswire.comForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesMay 13, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024May 13, 2024 | businesswire.comForte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateApril 10, 2024 | benzinga.comForte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, PredictionsApril 8, 2024 | markets.businessinsider.comBuy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market PositionMarch 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyNovember 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXNovember 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSeptember 14, 2023 | finance.yahoo.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingSeptember 6, 2023 | finance.yahoo.comConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomAugust 25, 2023 | businesswire.comConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersAugust 25, 2023 | 247wallst.comCamac Fund Now Owns 4.3% of Forte BiosciencesAugust 14, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 3, 2023 | benzinga.comChief Financial Officer At This Health Care Company Buys $149K of StockAugust 1, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102July 4, 2023 | finance.yahoo.comThis Forte Biosciences Insider Increased Their Holding In The Last YearSee More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today6/02/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+468.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.44% Return on Assets-85.68% Debt Debt-to-Equity RatioN/A Current Ratio9.45 Quick Ratio9.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book0.75Miscellaneous Outstanding Shares36,440,000Free Float32,605,000Market Cap$21.64 million OptionableOptionable Beta0.46 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $960.23kMr. Antony A. Riley CPA (Age 57)Chief Financial Officer Comp: $568.48kDr. Barbara K. Finck M.D. (Age 77)Chief Medical Clinician & Director Comp: $45kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsInflaRxNASDAQ:IFRXHillstream BioPharmaNASDAQ:HILSAssembly BiosciencesNASDAQ:ASMBSELLAS Life Sciences GroupNASDAQ:SLSOncolytics BiotechNASDAQ:ONCYView All CompetitorsInsidersPaul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)Paul A WagnerBought 36,203 shares on 12/7/2023Total: $20,997.74 ($0.58/share)Paul A WagnerBought 400 shares on 11/22/2023Total: $172.00 ($0.43/share)View All Insider Transactions FBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Forte Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FBRX shares. View FBRX analyst ratings or view top-rated stocks. What is Forte Biosciences' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price objectives for Forte Biosciences' stock. Their FBRX share price targets range from $2.75 to $4.00. On average, they expect the company's stock price to reach $3.38 in the next twelve months. This suggests a possible upside of 468.4% from the stock's current price. View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts. How have FBRX shares performed in 2024? Forte Biosciences' stock was trading at $0.8217 at the beginning of the year. Since then, FBRX shares have decreased by 27.7% and is now trading at $0.5938. View the best growth stocks for 2024 here. Are investors shorting Forte Biosciences? Forte Biosciences saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 25,100 shares, a drop of 12.8% from the April 30th total of 28,800 shares. Based on an average daily trading volume, of 25,800 shares, the days-to-cover ratio is presently 1.0 days. View Forte Biosciences' Short Interest. When is Forte Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our FBRX earnings forecast. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) announced its earnings results on Monday, March, 18th. The company reported ($0.04) earnings per share (EPS) for the quarter. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN). How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
